Omeicos Therapeutics used Rivia's platform to manage their Phase 2a clinical trial for OMT-28, a drug for Primary Mitochondrial Disease.
Stay Ahead with Rivia Insights
Join our newsletter for the latest industry trends, product updates, customer success stories, and partner highlights—delivered straight to your inbox.
FAQs